Ironwood (IRWD) Q3 2026 Earnings Call Transcript

Ironwood reported Q3 2026 revenue of $133 million, GAAP net income of $59.8 million and record adjusted EBITDA of $97.9 million, while raising full-year LINZESS U.S. sales guidance to $1.2 billion-$1.25 billion and total revenue guidance to $485 million-$510 million. Year-to-date LINZESS sales reached $880 million, and the company repaid $60 million of revolving debt, targeting less than $300 million outstanding at year-end. Ironwood said STARS-2 remains on track for estimated primary completion in October 2028, with a 2029 regulatory filing planned; Tammi Gaskins is scheduled to become CEO on Jan. 1, 2027.

Analysis

The key underwriting question is whether LINZESS growth is becoming volume-led or remains dependent on unusually favorable net-price and rebate dynamics. That distinction matters more in 2027: the reported Medicare price and broad-access strategy may support demand, but do not establish that current net revenue per prescription is sustainable once this year's pricing and rebate effects roll off. A strong Q4 could therefore be a poor proxy for the next year's earnings run rate.

IRWD has meaningful single-brand exposure: any deterioration in access, promotional returns, or net price would flow through collaboration economics and weaken the cash available for deleveraging and apraglutide. Conversely, AbbVie shares in LINZESS collaboration profits, but the supplied data do not establish materiality to AbbVie's consolidated results. The CEO handoff appears operationally continuous; the more consequential catalyst is STARS-2 execution, with primary completion estimated for October 2028 and a 2029 filing path. That is a long-duration, binary source of value, not a near-term earnings offset.

Near term, guidance delivery and cash conversion are the tests; over 1–3 months, watch Q4 commentary for 2027 pricing/access detail and evidence of site activation. Over 6–18 months, the market may shift from a turnaround multiple to a mature-brand valuation unless demand holds without comparable pricing support. Contrarian risk: investors may extrapolate this year's reported growth, while the less visible driver—net price—is less durable than prescriptions. No valuation or current price data are provided, so conviction sizing and entry levels cannot be responsibly specified.

Key Decisions for Investors

• Treat IRWD as a conditional long, not a momentum chase: add only after reviewing valuation and confirming that prescription growth persists alongside stable net price. Reassess if management lowers LINZESS guidance or reports weakening demand/access.
• At the next update, separate prescription growth from realized net price and rebate effects by channel. If volume holds but net price rolls over, reduce earnings estimates rather than extrapolating the 2026 run rate.
• Track cash conversion, collaboration receivable collection, and debt paydown together. A slowdown in collections or failure to approach the stated year-end debt target would weaken the deleveraging and apraglutide-funding thesis.
• Keep apraglutide as a catalyst watch, not a near-term valuation anchor: verify activated-site and enrollment progress at the next update; delays to the October 2028 primary-completion estimate would extend the pipeline-risk discount.
• Do not use ABBV as a direct hedge or mirror trade on this update: its collaboration exposure is real, but the article provides no basis to infer material consolidated earnings sensitivity.